Resistant Hypertension and Renal Nerve Denervation

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Nephrology

Background:

• Resistant hypertension poses significant cardiovascular risks.
• Limited therapeutic options exist for patients with resistant hypertension.
• Renal denervation (RDN) is an emerging nonpharmacologic treatment.

Purpose of the Study:

• To evaluate the efficacy of renal denervation (RDN) in patients with resistant hypertension.
• To address the conflicting results from previous RDN trials.
• To investigate potential reasons for the observed outcomes in the SYMPLICITY HTN-3 trial.

Main Methods:

• The SYMPLICITY HTN-3 trial compared RDN to a sham procedure in resistant hypertension patients.
• The study involved catheter-based ablation of renal sympathetic nerves.
• Key outcome measures included blood pressure reduction and cardiovascular events.

Main Results:

• The SYMPLICITY HTN-3 trial did not demonstrate superiority of RDN over the control group.
• A significant placebo effect was observed.
• The procedural effectiveness of RDN in the trial was questioned due to attenuated responses.

Conclusions:

• Current evidence suggests RDN may not be superior to sham procedures for resistant hypertension.
• Further research is needed to optimize RDN techniques and patient selection.
• The role of RDN in managing resistant hypertension requires clarification.